Is it time to advance the chemoprevention of environmental carcinogenesis with microdosing trials?
This perspective on Jubert et al. (beginning on page [1015] in this issue of the journal) discusses the use of microdosing with environmental carcinogens to accelerate the evaluation and optimization of chemopreventive interventions. The need for chemoprevention of environmental carcinogenesis is considered, as are the structure of microdosing, or phase 0, trials, technologies required to conduct microdose studies in this context, and ethical concerns. We also reflect on what microdosing studies have taught us to date.
Kensler
Thomas W
TW
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA. tkensler@jhsph.edu
Groopman
John D
JD
D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D002274:Carcinogens, Environmental / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*
D016588:Anticarcinogenic Agents; D002274:Carcinogens, Environmental